Why Reata Pharmaceuticals Stock is Down Today. See Also: Important News from Exelixis

Reata Pharmaceuticals: Why its Stock Price is Down
Reata Pharmaceuticals (RETA) announced that it has priced a public offering of 2,000,000 shares of its Class A common stock at a price to the public of $140.85 per share for gross proceeds of $281.7 million. Reata has granted the underwriters a 30-day option to purchase 300,000 additional . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.